Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities
Jonathan M. Spergel(University of Pennsylvania), Michael J. Cork(Royal Hallamshire Hospital), Chuanbo Zang(Pfizer (United States)), Michael S. Blaiss(Augusta University), Liza Takiya(Pfizer (United States)), Aharon Kessel(Technion – Israel Institute of Technology), Michael A. O’Connell(Pfizer (United States)), Wendy C. Cantrell(Children’s Village), John L. Werth(Pfizer (United States)), Peter Lio(Northwestern University)
Cited by 11
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k